Clinical observation on combined therapy of somatostatin with LipoPGE1 in treatment of 43 cases with severe acute pancreatitis

Objective: To evaluate the therapeutic effect of somatostatin combined with LipoPGE1 in treatment of patients with severe acute pancreatitis (SAP) and to explore its mechanism. Methods: Sixty-nine patients with SAP were allocated into the somatostatin combined with LipoPGE1 group (combination group) and the somatostatin group (control group). Changes of serum LPS, TNF-α, IL-6, GMP140, TXB2, vWF:Ag were determined. APACHEⅡ scores,Binder scores, average duration in ICU, mortality rate were compared between two groups before treatment and 14 days after treatment. Results: The serum level of LPS, TNF-α, IL-6,GMP140, TXB2, vWF:Ag were increased above normal levels in both groups, and descended after treatment. Compared with the control group, patients in combination group had a significant lower value of those parameters, as well as the APACHEⅡ and Binder scores (P0.05), the duration in ICU shortened and the mortality decreased significantly (P0.05). Conclusions: Combination use of somatostatin and LipoPGE1 could significantly inhibit the releasing of inflammatory media, improve the pancreas microcirculation and shorten the duration of stay in ICU.